Gilead and AEEH Launch €390,000 Grant Call to Boost Hepatitis D and C Efforts in Spain

Gilead Spain and Portugal, in collaboration with the Spanish Association for the Study of the Liver (AEEH), have announced the call for the eighth edition of their Gilead-AEEH Grants for projects to diagnose and link patients with Hepatitis D to the NHS and for Microelimination of Hepatitis C.

Gilead call will have a budget of 390,000 euros – 270,000 euros for HDV projects and 120,000 euros for HCV projects -,with a maximum of 30,000 euros per project.

Gilead backs 8th grant round to advance Hepatitis D diagnosis and Hepatitis C elimination in Spain

In the seven previous editions, the collaboration between Gilead and the AEEH has enabled the funding of 76 projects with a total amount of 1.8 million euros in 12 autonomous communities. This new call aims to continue promoting the implementation of projects for the diagnosis and linkage to the SNS of patients with Delta Hepatitis and the micro-elimination of Hepatitis C, which will be beneficial for patients, for our society and, ultimately, for the scientific community, through the granting of monetary contributions destined for their execution.

In the words of Marisa Álvarez, Executive Director of Medical Affairs at Gilead in Spain and Portugal, “The eighth edition of the Gilead-AEEH Grants for Projects to Diagnose and Connect Patients with the NHS with Hepatitis D and for Microelimination in Hepatitis C is a clear demonstration of our commitment as a company to patients suffering from liver disease. The more than 70 projects awarded to date, most of them multidisciplinary, have facilitated the diagnosis, referral, and cure of patients with hepatitis C and, at the same time, improved knowledge about Delta hepatitis, the most serious and aggressive of all viral hepatitis, in order to improve the management of patients affected by this virus.”

The deadline for submitting proposals will open on May 12th and run through June 21st of this year. Once again, the AEEH will be responsible for evaluating and selecting the projects, which must be submitted on the laboratory’s website.

“The scholarship program has allowed us to advance the strategy for eliminating hepatitis, in line with WHO programs , and has enabled us to maintain ongoing research activity in this field, generating patient care strategies that are, in some cases, exemplary and perfectly aligned with the goals of the AEEH,” said Rafael Bañares, president of the AEEH.

Gilead fights against Hepatitis D and C

Non-profit entities and beneficiaries of sponsorship, such as foundations, associations declared of public utility, public universities, Public Research Organizations dependent on the General State Administration, Health Research Institutes, and Public Research Consortiums affiliated with Public Research Organizations in the field of health sciences that were not awarded in the previous call, may benefit from the grant. A maximum of two projects may be submitted per healthcare center. A healthcare center will be defined as the one to which the principal investigator of the project is attached. Each principal investigator may only submit one research project proposal. The implementation period must not exceed 24 months.

The Gilead grants awarded during the seven previous editions (2018-2024) have promoted and provided resources to 55 HCV projects and 21 HDV projects, of which 28 have been aimed at the general population and primary care, 10 at the psychiatric population, 9 at the vulnerable/homeless population, 8 at the immigrant population, 8 at drug users, 6 at the population attended in emergency services, 2 at the surgical service , two at the population of penitentiary centers, and one at the populations of men who have sex with other men and post-Covid patients.

Furthermore, all of these grants offered by Gilead are widely distributed geographically across different regions and hospitals or healthcare institutions. Catalonia has been the region where the most projects have been developed under this program (20 in total), closely followed by Andalusia and Madrid (16 and 14, respectively).

In the Valencian Community, six projects have been developed, four in Castile and León, Galicia , and the Canary Islands, respectively; two in the Balearic Islands, Aragon , and Cantabria ; and one each in Navarre and La Rioja.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us